Canterbury DHB


Conjugated Oestrogens (e.g. Premarin)

Conjugated oestrogens shorten prolonged bleeding times and reduce or stop bleeding in patients with chronic renal failure. Mechanism of effect unknown.

Administered either intravenously or orally 0.6 mg/kg per day (approximately 50 mg) for four to five days. Anticipated 50% reduction in bleeding time for 7 to 14 days.

Can be used in uraemic patients together with desmopressin. Desmopressin provides an immediate short duration of effect (days).

Conjugated oestrogens are well tolerated in this setting with minimal side effects. The short duration of treatment (≤ five days) avoids adverse effects due to oestrogenic hormonal activity.

About this Canterbury DHB document (5308):

Document Owner:

Sean Macpherson (see Who's Who)

Last Reviewed:

November 2019

Next Review:

November 2022


Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 5308